GOOD DIVIDEND
KOTRA 0002 Share Price
RM7.15 RM5.52
52 Weeks Range : 3.82 - 6.97
5.0/10 (Expert Score)
Product is rated as #8 in category BM Health Care PROS:
- Profitable business
- High Dividend Yield
- Positive Cash Company
- Low Gearing Ratio
- High Trading Liquidity
CONS:
- Low Price-to-Tangible ratio
klse: Kotra Industries Bhd
Corporate Information
Board : Main
Shariah : Shariah Compliant
Sector : Pharmaceuticals Healthcare Products
Address: 1, 2&3, Jalan TTC 12, Cheng Industrial Estate, , 75250, Melaka
Contact: +606-3362222
Website: https://www.kotrapharma.com/
Corporate Background
Kotra Industries Berhad makes therapeutic products including anti-inflammatory, analgesic, antacids, cold and antitussive, anthelmentics, antidiabetics, antiasthmatics dermatological preparations, mouth and throat preparations, antiameobics, antihistamines, anti-emetics, and antivertigo. The Company also p roduces OTC products, energy drink booster, and mineral water.
Specification: KOTRA 0002
|
Result
Quarter Report History
| Date | Revenue,k | PBT,k | Net Profit,k |
|---|---|---|---|
| 24/02/23 | 62,251 | 16,554 | 16,411 |
| 29/11/22 | 64,752 | 18,351 | 18,240 |
| 29/08/22 | 48,767 | 12,353 | 16,236 |
| 30/05/22 | 55,244 | 17,095 | 17,037 |
| 24/02/22 | 52,817 | 13,909 | 13,904 |
| 26/11/21 | 51,089 | 14,922 | 14,918 |
| 02/09/21 | 43,475 | 14,305 | 12,439 |
| 28/05/21 | 43,342 | 6,243 | 6,246 |
| 19/02/21 | 38,178 | 3,233 | 3,226 |
| 20/11/20 | 34,627 | 2,492 | 2,479 |
| 14/08/20 | 36,763 | 4,174 | 7,905 |
| 22/05/20 | 46,507 | 7,630 | 7,617 |
Fundamental
Fundamental Analysis
| Last 4 Quarter Revenue (RM’000) | 231,014 |
|---|---|
| Last 4 Quarter Net Profit (RM’000) | 67,924 |
| Last 4 Quarter EPS (sen) | 45.9 |
| Last 4 Quarter PER | 12.03 |
| Last 4 Quarter Dividend (sen) | 10.00 |
| Last 4 Quarter Dividend Yield (%) | 1.81 |
| Net Tangible Assets (RM) | 1.65 |
| Goodwill (RM) | 0 |
| Cash (RM’000) | 91,110 |
| Debt (RM’000) | 3,510 |
| Total Debt (RM’000) | 58,040 |
| Net Assets (RM’000) | 255,130 |
| Current Ratio | 3.36 |
| Quick Ratio | 2.36 |
| Cash Ratio | 1.67 |
Technical
Technical Analysis
| MACD (26 vs 12) | -0.095 |
|---|---|
| Exponential Moving Average 5 | 5.789 |
| Exponential Moving Average 20 | 5.959 |
| Exponential Moving Average 90 | 5.77 |
| Relative Strength Index 14 | 0.36 |
| Stochastic %D 3 | 0.09 |
| Stochastic %K 14 | 0.04 |
11 reviews for KOTRA 0002
Show all Most Helpful Highest Rating Lowest Rating
Only logged in customers who have purchased this product may leave a review.
Over Optimistic
Top rated products
-
SUNVIEW 0262 ★★★★★RM0.75 - PETRONM 3042 ★★★★★
RM9.17RM4.35 - CMSB 2852 ★★★★★
RM2.23RM1.09 - MEDIAC 5090 ★★★★★
RM0.18RM0.16 - UMC 0256 ★★★★★RM0.78
BURSA MALAYSIA –
The Group recorded an increase in revenue of 32.78% to RM64.75 million as compared to RM48.77 million in the preceding quarter. This was mainly due to increase in sales of pharmaceutical products in the local market due to the surge in demand for medication, where there was a major shortage in the country. Moreover, export sales which were delayed in the previous quarter due to delay in issuance of import permits by the relevant countries, were shipped in current quarter. The Group recorded a profit before tax of RM18.35 million in the current quarter as compared to the profit before tax of RM12.35 million in the preceding quarter
BURSA MALAYSIA –
The Group recorded a profit before tax of RM12.35 million in the current quarter as compared to the profit before tax of RM17.10 million in the preceding quarter. This was attributed to lower sales achieved in current quarter. With lower sales, profit before tax was adversely impacted as certain expenses were relatively fixed in nature.
BURSA MALAYSIA –
The Group recorded a profit before tax of RM17.10 million in the current quarter as compared to the profit before tax of RM13.91 million in the preceding quarter. The increase in net profit before tax was mainly due to increase in sales and lower advertisement and promotional expenses incurred in current quarter.
BURSA MALAYSIA –
The Group recorded a profit before tax of RM13.91 million in the current quarter as compared to the profit before tax of RM14.92 million in the preceding quarter. The decrease was mainly due to higher selling and administration expenses incurred and higher promotional expenditure incurred to drive offtake at stores and to maintain brand awareness.
BURSA MALAYSIA –
The Group recorded a profit before tax of RM6.24 million in the current quarter as compared to the profit before tax of RM3.23 million in the preceding quarter. Increase in net profit after tax, including its margin in current quarter as compared to preceding quarter was mainly due to increase in sales and higher foreign exchange gain in current period.
BURSA MALAYSIA –
The Group recorded a profit before tax of RM2.49 million in the current quarter as compared to the profit before tax of RM4.17 million in the preceding quarter. Decrease in net profit before tax in current quarter as compared to preceding quarter was mainly due to decrease in sales.
REMUNERATION STUDY –
In Financial Year End 2020, the directors’ remuneration was 3.2 million. It was slightly high compared to average in listed companies, considering the employees’ remuneration of 43.6 million and auditor’s remuneration of 82 thousands
BURSA MALAYSIA –
For the quarter ended 30 June 2020, the Group recorded a decrease in revenue of 20.95% to RM36.76 million as compared to RM46.51 million in the preceding quarter. This was attributed to decrease in sales of health supplement to export markets and lower sales of pharmaceutical products to local markets.
BURSA MALAYSIA –
For the quarter ended 31 March 2020, the Group recorded a decrease in revenue of 4.87% to RM46.51 million as compared to RM48.89 million in the preceding quarter. This was attributed to decrease in sales to export markets for both the health supplements products and pharmaceutical products.The Group recorded a profit before tax of RM7.63 million in the current quarter as compared to the profit before tax of RM8.94 million in the preceding quarter. Decrease in net profit before tax was mainly due to decrease in sales.
INVESTING MALAYSIA –
12 MAR 20 – AmBank Research anticipates a flattish financial year 2020 (FY20) for KPJ Healthcare Bhd, amid expectations of higher tax and lower inpatient volume in the first half of this year.
BURSA MALAYSIA –
For the quarter ended 31 December 2019, the Group recorded a revenue of RM48.89 million and profit before tax of RM8.94 million as compared to revenue of RM39.57 million and profit before tax of RM5.18 million in the preceding quarter. Increase in revenue was mainly due to higher sales derived from both the local and export markets for health supplements products and higher sales achieved for pharmaceutical products in export markets. Increase in net profit after tax was mainly due to increase in sales.
REMUNERATION STUDY –
In Financial Year End 2019, the directors’ remuneration was 3.32 million. It was high compared to average in listed companies, considering the employees’ remuneration of 42.8 million and auditor’s remuneration of 74 thousands
Investing Malaysia –
Average investing volume for Kotra Industries Bhd in the past three months in stock market was 35.6k lots
Investing Malaysia –
KOTRA gets a score of 14.82 in our equity and assets quality test based on current share price of RM2.19
Investing Malaysia –
Kotra Industries Bhd gets a score of 18.93 in our stability test after the balance sheet, money statement study
Investing Malaysia –
Stock code of 0002 in Bursa Malaysia declared adjusted 0.02% dividend yield in past few years
Investing Malaysia –
KOTRA is estimated to have a profit consensus of 20.58 millions, with an adjusted market capitalization of 316.55 millions